Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chul Ahn

Showing results (521-530 of 539) with videos related to

Pageof 54
Sort By:
The Oncologist|March 19, 2017
Academic Cancer Center Phase I Program DevelopmentArthur E Frankel, Keith T Flaherty, George J Weiner, et al.
Nature Medicine|July 2, 2026
Polypill for heart failure with reduced ejection fraction: the POLY-HF randomized trialAmbarish Pandey, Neil Keshvani, Syed K Rizvi, et al.
European Heart Journal|October 12, 2017
Clinical implications of three-vessel fractional flow reserve measurement in patients with coronary artery diseaseJoo Myung Lee, Bon-Kwon Koo, Eun-Seok Shin, et al.
International Journal of Radiation Oncology, Biology, Physics|January 21, 2021
Cosmetic Outcomes of a Phase 1 Dose Escalation Study of 5-Fraction Stereotactic Partial Breast Irradiation for Early Stage Breast CancerAsal Rahimi, Howard E Morgan, Dong W Kim, et al.
The New England Journal of Medicine|April 10, 2024
Pragmatic Trial of Hospitalization Rate in Chronic Kidney DiseaseMiguel A Vazquez, George Oliver, Ruben Amarasingham, et al.
Nature Communications|March 12, 2024
The phosphatidylserine targeting antibody bavituximab plus pembrolizumab in unresectable hepatocellular carcinoma: a phase 2 trialDavid Hsiehchen, Muhammad S Beg, Radhika Kainthla, et al.
JTO Clinical and Research Reports|December 2, 2024
Clinical Outcomes of Maintenance Durvalumab After Definitive Concurrent Chemoradiotherapy in Unresectable Locally Advanced Stage III NSCLC According to EGFR and ALK Status: Korean Cancer Study Group LU-22-18Dae-Ho Choi, Miso Kim, Young Saing Kim, et al.
Human Molecular Genetics|November 26, 2009
Novel sequence feature variant type analysis of the HLA genetic association in systemic sclerosisDavid R Karp, Nishanth Marthandan, Steven G E Marsh, et al.
Cancer Discovery|January 9, 2025
Nonselective β-Adrenergic Receptor Inhibitors Impair Hematopoietic Regeneration in Mice and Humans after Hematopoietic Cell TransplantsJinsuke Nishino, Wenhuo Hu, Ashwin Kishtagari, et al.
European Journal of Cancer (Oxford, England : 1990)|December 10, 2020
Dynamic changes in circulating PD-1<sup>+</sup>CD8<sup>+</sup> T lymphocytes for predicting treatment response to PD-1 blockade in patients with non-small-cell lung cancerChang Gon Kim, Min Hee Hong, Kyung Hwan Kim, et al.
Pageof 54

Showing results (521-530 of 539) with videos related to

Sort By:
Pageof 54
The Oncologist|March 19, 2017
Academic Cancer Center Phase I Program DevelopmentArthur E Frankel, Keith T Flaherty, George J Weiner, et al.
Nature Medicine|July 2, 2026
Polypill for heart failure with reduced ejection fraction: the POLY-HF randomized trialAmbarish Pandey, Neil Keshvani, Syed K Rizvi, et al.
European Heart Journal|October 12, 2017
Clinical implications of three-vessel fractional flow reserve measurement in patients with coronary artery diseaseJoo Myung Lee, Bon-Kwon Koo, Eun-Seok Shin, et al.
International Journal of Radiation Oncology, Biology, Physics|January 21, 2021
Cosmetic Outcomes of a Phase 1 Dose Escalation Study of 5-Fraction Stereotactic Partial Breast Irradiation for Early Stage Breast CancerAsal Rahimi, Howard E Morgan, Dong W Kim, et al.
The New England Journal of Medicine|April 10, 2024
Pragmatic Trial of Hospitalization Rate in Chronic Kidney DiseaseMiguel A Vazquez, George Oliver, Ruben Amarasingham, et al.
Nature Communications|March 12, 2024
The phosphatidylserine targeting antibody bavituximab plus pembrolizumab in unresectable hepatocellular carcinoma: a phase 2 trialDavid Hsiehchen, Muhammad S Beg, Radhika Kainthla, et al.
JTO Clinical and Research Reports|December 2, 2024
Clinical Outcomes of Maintenance Durvalumab After Definitive Concurrent Chemoradiotherapy in Unresectable Locally Advanced Stage III NSCLC According to EGFR and ALK Status: Korean Cancer Study Group LU-22-18Dae-Ho Choi, Miso Kim, Young Saing Kim, et al.
Human Molecular Genetics|November 26, 2009
Novel sequence feature variant type analysis of the HLA genetic association in systemic sclerosisDavid R Karp, Nishanth Marthandan, Steven G E Marsh, et al.
Cancer Discovery|January 9, 2025
Nonselective β-Adrenergic Receptor Inhibitors Impair Hematopoietic Regeneration in Mice and Humans after Hematopoietic Cell TransplantsJinsuke Nishino, Wenhuo Hu, Ashwin Kishtagari, et al.
European Journal of Cancer (Oxford, England : 1990)|December 10, 2020
Dynamic changes in circulating PD-1<sup>+</sup>CD8<sup>+</sup> T lymphocytes for predicting treatment response to PD-1 blockade in patients with non-small-cell lung cancerChang Gon Kim, Min Hee Hong, Kyung Hwan Kim, et al.
Pageof 54